Key result
Genetically proxied agents acting on the renin-angiotensin system were significantly associated with a reduced risk of gastric cancer (OR 0.797; 95% CI 0.723-0.879; P < .001).
Why the study?
The study was conducted to investigate whether there is a causal relationship between agents acting on the renin-angiotensin system and gastric cancer using Mendelian randomization analysis.
Do agents acting on the renin-angiotensin system reduce the incidence of gastric cancer?
Observational
Do agents acting on the renin-angiotensin system reduce the incidence of gastric cancer?
Odds Ratio: 0.797 (95% CI 0.723–0.879)
p-value: p=< .001
Genetic evidence from a Mendelian randomization study suggests a potential causal relationship where agents acting on the renin-angiotensin system may reduce the risk of gastric cancer.
May support RAS agents lowering GC risk; leaves open need for trial confirmation before practice change.
The purpose of this study was to investigate whether there is a causal relationship between agents acting on the renin-angiotensin system (RAS) and gastric cancer (GC) using Mendelian randomization (MR) analysis. We conducted a two-sample MR analysis using publicly available Genome-Wide Association Study data. The inverse-variance weighted (IVW) method served as the primary analytical approach, while complementary methods, including weighted median, weighted mode, and MR-Egger regression, were also applied. Sensitivity analyses included MR-Egger regression to test for pleiotropy and the application of Cochran Q statistics via IVW and MR-Egger regression to assess heterogeneity. MR analysis demonstrated a significant inverse association between agents acting on the RAS and GC risk (IVW odds ratio = 0.797; 95% confidence interval: 0.723-0.879; P < .001). Sensitivity analyses showed no evidence of heterogeneity or horizontal pleiotropy, supporting the robustness and validity of the findings. These results suggest a potential causal relationship, highlighting the protective role of these agents in reducing GC risk. This study provides genetic evidence supporting a potential causal relationship between agents acting on the RAS and reduced GC risk, which requires further clinical validation.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) conducted an observational in Gastric cancer. Agents acting on the renin-angiotensin system (RAS) was evaluated on Gastric cancer risk (OR 0.797, 95% CI 0.723-0.879, p=< .001). Genetically proxied agents acting on the renin-angiotensin system were significantly associated with a reduced risk of gastric cancer (OR 0.797; 95% CI 0.723-0.879; P < .001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: